Podcast Episode Details
Back to Podcast Episodes
FF 81 Metformin Termination as explored by Target Trial Emulation
Season 1 Episode 81
The Filtrate
Joel Topf Bluesky: @kidneyboy.bsky.social
Jordy Cohen Bluesky: @jordybc.bsky.social
Swapnil Hiremath Bluesky: @hswapnil.medsky.social
Special Guest
Edouard “call me Ed” Fu Assistant Professor and Medical Student, and second author of his second paper covered on NephJC. LinkedIn | Leiden University Medical Center
Editing by
Simon Topf and Sophia Ambruso
The Kidney Connection written and performed by by Tim Yau
Show Notes
Ed’s first paper on NephJC: Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study (NephJC | BMJ)
Phenformin Wikipedia | Boca Raton News
The metformin black box (as part of the FDA Label)
WARNING: LACTIC ACIDOSIS
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metforminassociated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL (see PRECAUTIONS).
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk gro
Published on 3 months, 3 weeks ago